Elisa Biamino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elisa Biamino has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Alfredo Brusco
Department of Neurosciences Rita Levi-Montalcini, University of Torino, Turin, Italy
2 shared publications - Alessandra Longo
Molecular Pathology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy
1 shared publication - Alessandra Magistrato
CNR-IOM at SISSA, via Bonomea 265, 34136 Trieste, Italy
1 shared publication - Alessandra Spano
Department of Pediatrics, Regina Margherita Children’s Hospital, Turin, Italy
1 shared publication - Alessandro Mussa
Department of Public Health and Pediatric Sciences University of Torino Torino Italy
1 shared publication - Benjamin Cogné
Nantes Université, CHU de Nantes, CNRS, INSERM, l’institut du thorax, Nantes, France
1 shared publication
Latest Publications
- Open Access
- 19 February 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1)
A novel spliceosomopathy caused by de novo SF3B3 variants
Spliceosomopathies are syndromes caused by pathogenic variants in genes involved in splicing and mRNA metabolism. Here, we report a novel spliceosomopathy
- 19 February 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1)
Open AccessA novel spliceosomopathy caused by de novo SF3B3 variants
Spliceosomopathies are syndromes caused by pathogenic variants in genes involved in splicing and mRNA metabolism. Here, we report a novel spliceosomopathy
- Open Access
Expanding Clinical and Genetic Landscape of SATB2-Associated Syndrome
Background: SATB2-associated syndrome (SAS), also known as Glass syndrome, is a neurodevelopmental disorder (NDD) characterized by intellectual disability, developmental delay, absent or limited speech, and distinctive craniofacial and dental anomalies. It is caused by autosomal dominant pathogenic variants in the SATB2 gene, which plays a crucial role in brain, dental, and jaw development. Due to its variable phenotype, clinical diagnosis can be challenging, necessitating genetic confirmation. Methods: We present six new cases of SAS with SATB2 germline variants identified through next generation sequencing (NGS) technologies, expanding the known genetic and clinical spectrum of the syndrome. Detailed clinical phenotyping was performed for all patients. Results: Our cohort exhibits a broad range of clinical manifestations consistent with SAS, encompassing severe intellectual disability, profound speech delay, various palatal and dental abnormalities. We report the oldest adult patient (56 years old) carrying an in-frame duplication, and a pediatric patient with a missense variant who presented a significant reduction in visual acuity, likely of neurological or cortical origin, in the absence of ophthalmological abnormalities. SATB2 variants include three missenses, two in-frame deletion/duplication and one frameshift variant, several of which are novel and classified as likely pathogenic or pathogenic according to ACMG guidelines. Conclusions: This report provides new clinical and genetic insights into the landscape of SAS. Our findings confirm the phenotypic heterogeneity of SAS and highlight the critical role of comprehensive genetic testing for accurate diagnosis in NDD patients.
Open AccessExpanding Clinical and Genetic Landscape of SATB2-Associated Syndrome
Background: SATB2-associated syndrome (SAS), also known as Glass syndrome, is a neurodevelopmental disorder (NDD) characterized by intellectual disability, developmental delay, absent or limited speech, and distinctive craniofacial and dental anomalies. It is caused by autosomal dominant pathogenic variants in the SATB2 gene, which plays a crucial role in brain, dental, and jaw development. Due to its variable phenotype, clinical diagnosis can be challenging, necessitating genetic confirmation. Methods: We present six new cases of SAS with SATB2 germline variants identified through next generation sequencing (NGS) technologies, expanding the known genetic and clinical spectrum of the syndrome. Detailed clinical phenotyping was performed for all patients. Results: Our cohort exhibits a broad range of clinical manifestations consistent with SAS, encompassing severe intellectual disability, profound speech delay, various palatal and dental abnormalities. We report the oldest adult patient (56 years old) carrying an in-frame duplication, and a pediatric patient with a missense variant who presented a significant reduction in visual acuity, likely of neurological or cortical origin, in the absence of ophthalmological abnormalities. SATB2 variants include three missenses, two in-frame deletion/duplication and one frameshift variant, several of which are novel and classified as likely pathogenic or pathogenic according to ACMG guidelines. Conclusions: This report provides new clinical and genetic insights into the landscape of SAS. Our findings confirm the phenotypic heterogeneity of SAS and highlight the critical role of comprehensive genetic testing for accurate diagnosis in NDD patients.